Navigation Links
New research to cut animal testing

Researchers at The University of Manchester have been awarded £130,000 to develop new techniques to reduce the need for animals in drug testing.

Current checks to establish whether a new drug is carcinogenic can be inconclusive and require further testing on live animals to establish whether they are harmful or not.

Dr Richard Walmsley and colleagues at the University spin-out company he founded, Gentronix, have developed techniques using cultured human cells to more effectively weed out cancer-causing compounds.

"The current pre-animal tests that are used are highly sensitive and so most carcinogens are identified," said Dr Walmsley, who is based in the Faculty of Life Sciences.

"Unfortunately, such tests have poor specificity and a lot of safe compounds are also wrongly identified as potential carcinogens. This means that animal testing is still carried out, in case such compounds turn out to be safe.

"The testing process developed at Gentronix has proven very reliable at telling us whether a drug will cause cancer but some chemicals, called promutagens, only become carcinogenic once they have passed through the body's liver.

"This grant will help us develop new non-animal experiments to identify these other toxic compounds and so reduce the need for animal testing."

The funding ?awarded by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) ?will help the scientists establish new genotoxicity tests using cultured human liver cells.

It is hoped the new test will not only reduce the number of compounds that are tested on animals but also ensure harmless chemicals that could prove to be useful new drugs are not falsely labelled as carcinogens.

"I don't believe that animal testing will disappear from drug safety assessment in the short term as you can't ask human volunteers to take novel drugs straight from testing done in tube tests," said Dr Walmsley.

"But if we can refine the pre-animal tests and increase people's confidence in them, then we will be able to reduce the number of chemicals that are tested on live animals."


'"/>

Source:University of Manchester


Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/18/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, will feature data from two clinical studies ... ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in ... Napabucasin is an orally-administered investigational agent designed to inhibit ... stem cells (CSCs) possess the property of stemness – ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse ... expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables ... is planned for further growth in 2017. Extractable & Leachable evaluations have become ...
(Date:1/18/2017)... Chicago, IL (PRWEB) , ... January 18, 2017 ... ... auction on January 24th, 2017, to sell research and genetic testing lab equipment ... of service in the Northwest and Northeast regions of the United States. This ...
(Date:1/18/2017)... 18, 2017  Caris Life Sciences, a leading ... the largest private funder of pancreatic cancer research, ... the impact of immunotherapy in the treatment of ... services to identify potential trial candidates based on ... physicians and study investigators. The Lustgarten Foundation is ...
Breaking Biology Technology: